

ARMD: That was then, this is now.

COPE ID: 29986-PS

Michael E. Feeser OD,FAAO

- I. AMD Categories
 - a. CAT 1
 - b. CAT 2
 - c. CAT 3
 - d. CAT 4
- II. AREDS Formula
- III. AREDS Results
- IV. AREDS 2
 - a. Purpose
 - b. Outcomes
 - c. Secondary Outcomes
 - d. Eligibility Criteria
 - e. Inclusion/Exclusion Criteria
- V. Cochrane Review
- VI. Advanced AMD
 - a. Geographic Atrophy
 - i. Fundus Autofluorescence
 - ii. Process leading to Geographic Atrophy
 - b. Choroidal Neovascularization
- VII. AMD Risk Factors
- VIII. Oxidative Stress/Oxidative DNA
 - a. High Oxygen
 - b. Intense Light Exposure
 - c. Presence of photo sensitizers (lipofuscin)
- IX. Pathways based Treatment Paradigm
 - a. Oxidative Damage
 - b. Excessive lipofuscin accumulation
 - c. Chronic RPE/Bruchs Membrane/Choriocapillaris Inflammation
 - d. Complement Pathways Mutations
 - e. Compromised Complement Regulation
- X. Angiogenesis
 - a. Angiogenic Factor Production
 - b. Factor Release
 - c. Binding of factors to extracellular receptors

- d. Endothelial Cell Activation
 - e. Endothelial Cell Proliferation
 - f. Directed Endothelial Cell Migration
 - g. Extracellular Matrix Remodeling
 - h. Tube Formation
 - i. Vascular Stabilization
- XI. The Visual Cycle
 - XII. Complement Pathway
 - XIII. Antiangiogenesis Therapies